Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy

International Immunology

Volumn 27, Issue 1, 2015, Pages 31-37

  Zimmerman, Zachary ^a   Maniar, Tapan ^a   Nagorsen, Dirk ^a  

^a AMGEN INC   (United States)

Author keywords

bi specific antibody; BiTE ; Immunotherapy; Leukemia; Lymphoma

Indexed keywords

ANTIBODY; BISPECIFIC T CELL ENGAGER ANTIBODY; BLINATUMOMAB; CD19 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD3 ANTIGEN; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL DEVELOPMENT PLAN; CYTOTOXIC T LYMPHOCYTE; DRUG SYNTHESIS; FATIGUE; FEVER; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RIGOR; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84922466555     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu089     Document Type: Article

References (42)

1. Dinner, S., Lee, D. and Liedtke, M. 2014. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leuk. Lymphoma. 55:1715.
2. Maxwell, S. A. and Mousavi-Fard, S. 2013. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp. Biol. Med. (Maywood) 238:971.
3. Parmar, S. and Ritchie, D. S. 2014. Allogeneic transplantation as anticancer immunotherapy. Curr. Opin. Immunol. 27c:38.
4. Plosker, G. L. and Figgitt, D. P. 2003. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803.
5. Okroj, M., Österborg, A. and Blom, A. M. 2013. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat. Rev. 39:632.
6. Mittal, D., Gubin, M. M., Schreiber, R. D. and Smyth, M. J. 2014. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr. Opin. Immunol. 27C:16.
7. Staerz, U. D., Kanagawa, O. and Bevan, M. J. 1985. Hybrid antibodies can target sites for attack by T cells. Nature 314:628.
8. Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A. and Segal, D. M. 1985. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354.
9. Fournier, P. and Schirrmacher, V. 2013. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 27:35.
10. Müller, D. and Kontermann, R. E. 2010. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 24:89.
11. Mack, M., Riethmüller, G. and Kufer, P. 1995. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl Acad. Sci. USA 92:7021.
12. Löffler, A., Kufer, P., Lutterbüse, R. et al. 2000. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098.
13. Wang, K., Wei, G. and Liu, D. 2012. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1:36.
14. Barrett, D., Brown, V. I., Grupp, S. A. and Teachey, D. T. 2012. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs 14:299.
15. Khwaja, A. 2010. PI3K as a target for therapy in haematological malignancies. Curr. Top. Microbiol. Immunol. 347:169.
16. Brandl, C., Haas, C., d'Argouges, S. et al. 2007. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol. Immunother. 56:1551.
17. Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. and Baeuerle, P. A. 2006. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43:763.
18. Dreier, T., Lorenczewski, G., Brandl, C. et al. 2002. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100:690.
19. Gruen, M., Bommert, K. and Bargou, R. C. 2004. T-cell-mediated lysis of B cells induced by a CD19×CD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol. Immunother. 53:625.
20. Kufer, P., Zettl, F., Borschert, K., Lutterbüse, R., Kischel, R. and Riethmüller, G. 2001. Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun. 1:10.
21. Hoffmann, P., Hofmeister, R., Brischwein, K. et al. 2005. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/ CD3-bispecific single-chain antibody construct. Int. J. Cancer 115:98.
22. Dreier, T., Baeuerle, P. A., Fichtner, I. et al. 2003. T cell costimulusindependent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170:4397.
23. Schlereth, B., Quadt, C., Dreier, T. et al. 2006. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol. Immunother. 55:503.
24. Nagorsen, D., Kufer, P., Baeuerle, P. A. and Bargou, R. 2012. Blinatumomab: a historical perspective. Pharmacol. Ther. 136:334.
25. Klinger, M., Brandl, C., Zugmaier, G. et al. 2012. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119:6226.
26. Cheadle, E. J., Gornall, H., Baldan, V., Hanson, V., Hawkins, R. E. and Gilham, D. E. 2014. CAR T cells: driving the road from the laboratory to the clinic. Immunol. Rev. 257:91.
27. Goebeler, M., Viardot, A., Noppeney, R. et al. 2011. Blinatumomab (CD3/CD19 Bite (R) Antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL).Ann. Oncol. (ICML). 22:190.
28. Topp, M. S., Kufer, P., Gökbuget, N. et al. 2011. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29:2493.
29. Martelli, M., Ferreri, A. J., Agostinelli, C., Di Rocco, A., Pfreundschuh, M. and Pileri, S. A. 2013. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 87:146.
30. Viardot, A., Goebeler, M., Noppeney, R. et al. 2011. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. ASH Annual Meeting Abstracts 118:1637.
31. Goebeler, M., Pfreundschuh, M., Adrian, N. et al. 2013. Openlabel phase 2 study of the bispecific T-cell engager (BiTE®) blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 122:1811.
32. Wu, B., Hijazi, Y., Wolf, A., Brandl, C., Sun, Y.-N. and Zhu, M. 2013. Pharmacokinetics (PK) of blinatumomab and its clinical implications. ASCO Meeting Abstracts 31:3048.
33. Bassan, R., Spinelli, O., Oldani, E. et al. 2009. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113:4153.
34. Raff, T., Gökbuget, N., Lüschen, S. et al.; GMALL Study Group. 2007. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109:910.
35. Gandemer, V., Pochon, C., Oger, E. et al. 2014. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual diseaseguided protocol. Br. J. Haematol. 165:392.
36. Salah-Eldin, M., Abousamra, N. K. and Azzam, H. 2014. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study. Med. Oncol. 31:938.
37. Topp, M. S., Gökbuget, N., Zugmaier, G. et al. 2012. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:5185.
38. Topp, M. S., Goekbuget, N., Zugmaier, G. et al. 2011. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. ASH Annual Meeting Abstracts 118:252.
39. Bhojwani, D. and Pui, C. H. 2013. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 14:e205.
40. Handgretinger, R., Zugmaier, G., Henze, G., Kreyenberg, H., Lang, P. and von Stackelberg, A. 2011. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25:181.
41. Schlegel, P., Lang, P., Zugmaier, G. et al. 2014. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 99:1212.
42. Zugmaier, G., Handgretinger, R., Locatelli, F. et al. 2013. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/ refractory B-cell precursor acute lymphoblastic leukemia. Blood 122:70.